Chen Guo-lin, Hu Huai-dong, Ma Ying-ji, Li Yong-guo, Xue Qiong, Chen Min, Ren Hong
Institute for Viral Hepatitis, Chongqing University of Medical Sciences, Chongqing 400010, China.
Zhonghua Gan Zang Bing Za Zhi. 2006 Jun;14(6):431-4.
To investigate the cure effect of tumor antigen specific CTL on a model of human hepatocellular carcinoma in nude mice LCI-D20.
Dendritic cells (DCs) were induced from peripheral blood mononuclear cells of healthy people in vitro by using recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and interleukin-4 (rhIL-4) and were pulsed with tumor antigen from hepatocellular carcinoma cell line MHCC97H. Then tumor antigen specific cytotoxic T lymphocytes (CTLs) were induced. By intraperitoneal injection of tumour antigen specific CTLs into the LCI-D20, the preventive and therapeutic effects of these CTLs to HCC in the LCI-D20 model were assessed. Cytokine-induced killer (CIK) cells and phosphate buffer solution were used as controls at the same time.
The weights of tumors in the tumor antigen specific CTL group, in the CIK cell group and in the blank group were (1.11+/-0.63), (1.12+/-0.36) and (2.68+/-0.53) grams respectively (t = 5.18, t = 6.06, P < 0.01). The amount of blood alpha fetal protein in the tumor antigen specific CTL and CIK groups were (52.1+/-9.7) microg/L and (48.6+/-5.2) microg/L, and was (82.2+/-7.2) microg/L in the blank group (t = 17.26, t = 22.07, P < 0.01 respectively). The metastasis rates in livers were 16.7%, 16.7% and 58.3% in the tumor antigen specific CTL, CIK cell and blank control groups respectively (chi2= 4.44, P < 0.01). The survival time of the mice in the tumor antigen specific CTL group was (79.0+/-5.02) days, (73.3+/-7.0) days in the CIK group, and (52.3+/-5.2) days in the blank group (t = 14.56, t = 17.54, P < 0.01).
Tumor antigen specific CTLs may prevent metastasis in the LCI-D20 model and prolong the survival time.
研究肿瘤抗原特异性细胞毒性T淋巴细胞（CTL）对人肝癌裸鼠LCI-D20模型的治疗效果。
采用重组人粒细胞-巨噬细胞集落刺激因子（rhGM-CSF）和白细胞介素-4（rhIL-4）从健康人外周血单个核细胞体外诱导树突状细胞（DCs），并用肝癌细胞系MHCC97H的肿瘤抗原脉冲处理。然后诱导肿瘤抗原特异性细胞毒性T淋巴细胞（CTLs）。通过腹腔注射肿瘤抗原特异性CTLs到LCI-D20中，评估这些CTLs对LCI-D20模型中肝癌的预防和治疗效果。同时使用细胞因子诱导的杀伤细胞（CIK）和磷酸盐缓冲溶液作为对照。
肿瘤抗原特异性CTL组、CIK细胞组和空白组的肿瘤重量分别为（1.11±0.63）、（1.12±0.36）和（2.68±0.53）克（t = 5.18，t = 6.06，P < 0.01）。肿瘤抗原特异性CTL组和CIK组的血甲胎蛋白量分别为（52.1±9.7）μg/L和（48.6±5.2）μg/L，空白组为（82.2±7.2）μg/L（t = 17.26，t = 22.07，P < 0.01）。肿瘤抗原特异性CTL组、CIK细胞组和空白对照组的肝转移率分别为16.7%、16.7%和58.3%（χ2 = 4.44，P < 0.01）。肿瘤抗原特异性CTL组小鼠的生存时间为（79.0±5.02）天，CIK组为（73.3±7.0）天，空白组为（52.3±5.2）天（t = 14.56，t = 17.54，P < 0.01）。
肿瘤抗原特异性CTLs可预防LCI-D20模型中的转移并延长生存时间。
